Skip to main content
AstraZenecaRevenue

AstraZeneca Pharma India Reports 30% Revenue Growth, Crosses Rs 7,291 Mn

Source: Autobound Signal API · 84 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca Pharma India reported a 30 percent year-on-year growth in revenue from operations to Rs 7,291 million in Q2 FY2026-27.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Strong performance across oncology, biopharmaceuticals and rare diseases, alongside regulatory approvals and state-level healthcare partnerships, drives growth AstraZeneca Pharma India Limited reported a 30 per cent year-on-year growth in revenue from operations to Rs 7,291 million in the second quarter of FY2026-27, covering July to September 2026, driven by sustained performance across its oncology, biopharmaceuticals and rare disease portfolios. The company also reported a 30 per cent increase in revenue for the first half of FY2026-27, reaching Rs 14,119 million, compared with Rs 10,854 million in the corresponding period last year. The company attributed its performance to operational efficiency, portfolio expansion and increasing adoption of innovative therapies addressing unmet medical needs in India. Oncology remained the largest contributor, generating Rs 5,085 million in Q2, compared with Rs 3,978 million in the year-ago quarter. Revenue from biopharmaceuticals, covering cardiovascular, renal and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immunotherapies (V&I), stood at Rs 1,610 million, against Rs 1,268 million previously. The rare diseases segment recorded revenue of Rs 204 million, compared with Rs 38 million in the corresponding quarter last year. Regulatory Approvals And Expansion Commenting on the results, Praveen Rao Akkinepally...

Keep reading with a free account

The rest of this article, and every signal for AstraZeneca, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Location
India

The full record

From the Signal API record

Numbers

Amount (USD)
$77.6M

Extraction

Confidence
95%
Detected
Nov 7, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/099a7ecd-1636-38f3-1a88-6167088493ac returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "099a7ecd-1636-38f3-1a88-6167088493ac",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-11-07T12:31:12+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/moodys:f2cf95883959e:0-astrazeneca-pharma-india-reports-30-revenue-growth-crosses-rs-7-291-mn/",
    "title": "AstraZeneca Pharma India Reports 30% Revenue Growth, Crosses Rs 7,291 Mn - TradingView",
    "excerpt": "Strong performance across oncology, biopharmaceuticals and rare diseases, alongside regulatory approvals and state-level healthcare partnerships, drives growth AstraZeneca Pharma India Limited reported a 30 per cent year-on-year growth in revenue from operations to Rs 7,291 million in the second quarter of FY2026-27, covering July to September 2026, driven by sustained performance across its oncology, biopharmaceuticals and rare disease portfolios. The company also reported a 30 per cent increase in revenue for the first half of FY2026-27, reaching Rs 14,119 million, compared with Rs 10,854 million in the corresponding period last year. The company attributed its performance to operational efficiency, portfolio expansion and increasing adoption of innovative therapies addressing unmet medical needs in India. Oncology remained the largest contributor, generating Rs 5,085 million in Q2, compared with Rs 3,978 million in the year-ago quarter. Revenue from biopharmaceuticals, covering cardiovascular, renal and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immunotherapies (V&I), stood at Rs 1,610 million, against Rs 1,268 million previously. The rare diseases segment recorded revenue of Rs 204 million, compared with Rs 38 million in the corresponding quarter last year. Regulatory Approvals And Expansion Commenting on the results, Praveen Rao Akkinepally...",
    "summary": "AstraZeneca Pharma India reported a 30 percent year-on-year growth in revenue from operations to Rs 7,291 million in Q2 FY2026-27.",
    "location": "India",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.95,
    "published_at": "2026-11-07T12:31:12Z",
    "location_data": [
      {
        "region": "Southern Asia",
        "country": "India",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "AstraZeneca Pharma India Limited reported a 30 per cent year-on-year growth in revenue from operations to Rs 7,291 million in the second quarter of FY2026-27, covering July to September 2026, driven by sustained performance across its oncology, biopharmaceuticals and rare disease portfolios.",
    "amount_normalized": 77634568
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.